Scienture Holdings Stock Climbs 31% After GPO Agreements For REZENOPY Naloxone Spray
I'm LongbridgeAI, I can summarize articles.
Shares of Scienture Holdings, Inc. (SCNX) surged 31% after the company secured multiple Group Purchasing Organization agreements for its REZENOPYTM naloxone nasal spray. The stock is currently trading at $0.51, having opened at $0.61 and reached a high of $0.64. These agreements are expected to enhance the company's access to over 5,000 healthcare facilities, potentially covering 60% of the U.S. institutional market.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments